Received Jan 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 2ME34 | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2ME34 | — |
administration of two pediatric doses of Engerix-B to an adult; administration of two pediatric doses of Engerix-B to an adult; drug dose administration interval too long; administration of two pediatric doses of Engerix-B to an adult; administration of two pediatric doses of Engerix-B to an adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 59-year-old female patient who received HBV (Engerix B pediatric) (batch number 2ME34, expiry date 15-JUL-2026) for prophylaxis. Co-suspect products included HBV (Engerix B pediatric) (batch number 2ME34, expiry date 15-JUL-2026) for prophylaxis. On 18-JUN-2025, the patient received the 1st dose of Engerix B pediatric. On 29-JUL-2025, the patient received the 2nd dose of Engerix B pediatric. On 18-JUN-2025, an unknown time after receiving Engerix B pediatric and Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: administration of two pediatric doses of Engerix-B to an adult) and underdose (Verbatim: administration of two pediatric doses of Engerix-B to an adult). On 29-JUL-2025, the patient experienced adult use of a child product (Verbatim: administration of two pediatric doses of Engerix-B to an adult), underdose (Verbatim: administration of two pediatric doses of Engerix-B to an adult) and drug dose administration interval too long (Verbatim: drug dose administration interval too long). The outcome of the adult use of a child product, underdose, adult use of a child product, underdose and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.